Sickle Cell Disease and Stroke

Cerebral infarction is a common complication of sickle cell disease and may manifest as overt stroke or cognitive impairment associated with “silent” cerebral infarction on magnetic resonance imaging. Vasculopathy may be diagnosed on transcranial Doppler or magnetic resonance angiography. The risk f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric neurology 2019-06, Vol.95, p.34-41
Hauptverfasser: Hirtz, Deborah, Kirkham, Fenella J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 41
container_issue
container_start_page 34
container_title Pediatric neurology
container_volume 95
creator Hirtz, Deborah
Kirkham, Fenella J.
description Cerebral infarction is a common complication of sickle cell disease and may manifest as overt stroke or cognitive impairment associated with “silent” cerebral infarction on magnetic resonance imaging. Vasculopathy may be diagnosed on transcranial Doppler or magnetic resonance angiography. The risk factors in sickle cell disease for cognitive impairment, overt ischemic stroke, silent cerebral infarction, overt hemorrhagic stroke, and vasculopathy defined by transcranial Doppler or magnetic resonance angiography overlap, with severe acute and chronic anemia, acute chest crisis, reticulocytosis, and low oxygen saturation reported with the majority. However, there are differences reported in different cohorts, which may reflect age, geographic location, or neuroimaging techniques, for example, magnetic resonance imaging field strength. Regular blood transfusion reduces, but does not abolish, the risk of neurological complications in children with sickle cell disease and either previous overt stroke or silent cerebral infarction or abnormal transcranial Doppler. There are relatively few data on the use of hydroxyurea or other management strategies. Early assessment of the risk of neurocognitive complications is likely to become increasingly important in the management of sickle cell disease.
doi_str_mv 10.1016/j.pediatrneurol.2019.02.018
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2204694108</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0887899418313055</els_id><sourcerecordid>2204694108</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-d2c7c3681335c02829103a877263d50504c12aea5a83be4b98f7244c434f86093</originalsourceid><addsrcrecordid>eNqNkE1Lw0AQhhdRbK3-hRLw4iVx9iPJLp6k1g8oeKiel-1mAtumSd1NBP-9W1oFb57m8rzvzDyEXFPIKNDidp3tsHKm9y0OvmsyBlRlwDKg8oSMqSx5mtMcTskYpCxTqZQYkYsQ1gCQKybOyYiDEpKKckymS2c3DSYzbJrkwQU0ARPTVsmy990GL8lZbZqAV8c5Ie-P87fZc7p4fXqZ3S9SK3jRpxWzpeWFpJznFphkigI3sixZwascchCWMoMmN5KvUKyUrEsmRAyLWhag-ITcHHp3vvsYMPR664KNN5kWuyFoxkAUSlCQEb07oNZ3IXis9c67rfFfmoLeC9Jr_UeQ3gvSwHQUFNPT46JhtcXqN_tjJALzA4Dx3U-HXgfrsLWx0aPtddW5fy36BiGne6Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2204694108</pqid></control><display><type>article</type><title>Sickle Cell Disease and Stroke</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Hirtz, Deborah ; Kirkham, Fenella J.</creator><creatorcontrib>Hirtz, Deborah ; Kirkham, Fenella J.</creatorcontrib><description>Cerebral infarction is a common complication of sickle cell disease and may manifest as overt stroke or cognitive impairment associated with “silent” cerebral infarction on magnetic resonance imaging. Vasculopathy may be diagnosed on transcranial Doppler or magnetic resonance angiography. The risk factors in sickle cell disease for cognitive impairment, overt ischemic stroke, silent cerebral infarction, overt hemorrhagic stroke, and vasculopathy defined by transcranial Doppler or magnetic resonance angiography overlap, with severe acute and chronic anemia, acute chest crisis, reticulocytosis, and low oxygen saturation reported with the majority. However, there are differences reported in different cohorts, which may reflect age, geographic location, or neuroimaging techniques, for example, magnetic resonance imaging field strength. Regular blood transfusion reduces, but does not abolish, the risk of neurological complications in children with sickle cell disease and either previous overt stroke or silent cerebral infarction or abnormal transcranial Doppler. There are relatively few data on the use of hydroxyurea or other management strategies. Early assessment of the risk of neurocognitive complications is likely to become increasingly important in the management of sickle cell disease.</description><identifier>ISSN: 0887-8994</identifier><identifier>EISSN: 1873-5150</identifier><identifier>DOI: 10.1016/j.pediatrneurol.2019.02.018</identifier><identifier>PMID: 30948147</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Anemia, Sickle Cell - complications ; Anemia, Sickle Cell - diagnostic imaging ; Anemia, Sickle Cell - therapy ; Blood Transfusion - trends ; Cerebral blood flow ; Cerebrovascular Circulation - physiology ; Hemorrhage ; Humans ; Hydroxyurea ; Hydroxyurea - therapeutic use ; Silent infarction ; Stroke - diagnostic imaging ; Stroke - etiology ; Stroke - therapy ; Transcranial Doppler ; Transfusion therapy ; Ultrasonography, Doppler, Transcranial - trends</subject><ispartof>Pediatric neurology, 2019-06, Vol.95, p.34-41</ispartof><rights>2019</rights><rights>Copyright © 2019. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-d2c7c3681335c02829103a877263d50504c12aea5a83be4b98f7244c434f86093</citedby><cites>FETCH-LOGICAL-c436t-d2c7c3681335c02829103a877263d50504c12aea5a83be4b98f7244c434f86093</cites><orcidid>0000-0002-2443-7958</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0887899418313055$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30948147$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hirtz, Deborah</creatorcontrib><creatorcontrib>Kirkham, Fenella J.</creatorcontrib><title>Sickle Cell Disease and Stroke</title><title>Pediatric neurology</title><addtitle>Pediatr Neurol</addtitle><description>Cerebral infarction is a common complication of sickle cell disease and may manifest as overt stroke or cognitive impairment associated with “silent” cerebral infarction on magnetic resonance imaging. Vasculopathy may be diagnosed on transcranial Doppler or magnetic resonance angiography. The risk factors in sickle cell disease for cognitive impairment, overt ischemic stroke, silent cerebral infarction, overt hemorrhagic stroke, and vasculopathy defined by transcranial Doppler or magnetic resonance angiography overlap, with severe acute and chronic anemia, acute chest crisis, reticulocytosis, and low oxygen saturation reported with the majority. However, there are differences reported in different cohorts, which may reflect age, geographic location, or neuroimaging techniques, for example, magnetic resonance imaging field strength. Regular blood transfusion reduces, but does not abolish, the risk of neurological complications in children with sickle cell disease and either previous overt stroke or silent cerebral infarction or abnormal transcranial Doppler. There are relatively few data on the use of hydroxyurea or other management strategies. Early assessment of the risk of neurocognitive complications is likely to become increasingly important in the management of sickle cell disease.</description><subject>Anemia, Sickle Cell - complications</subject><subject>Anemia, Sickle Cell - diagnostic imaging</subject><subject>Anemia, Sickle Cell - therapy</subject><subject>Blood Transfusion - trends</subject><subject>Cerebral blood flow</subject><subject>Cerebrovascular Circulation - physiology</subject><subject>Hemorrhage</subject><subject>Humans</subject><subject>Hydroxyurea</subject><subject>Hydroxyurea - therapeutic use</subject><subject>Silent infarction</subject><subject>Stroke - diagnostic imaging</subject><subject>Stroke - etiology</subject><subject>Stroke - therapy</subject><subject>Transcranial Doppler</subject><subject>Transfusion therapy</subject><subject>Ultrasonography, Doppler, Transcranial - trends</subject><issn>0887-8994</issn><issn>1873-5150</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1Lw0AQhhdRbK3-hRLw4iVx9iPJLp6k1g8oeKiel-1mAtumSd1NBP-9W1oFb57m8rzvzDyEXFPIKNDidp3tsHKm9y0OvmsyBlRlwDKg8oSMqSx5mtMcTskYpCxTqZQYkYsQ1gCQKybOyYiDEpKKckymS2c3DSYzbJrkwQU0ARPTVsmy990GL8lZbZqAV8c5Ie-P87fZc7p4fXqZ3S9SK3jRpxWzpeWFpJznFphkigI3sixZwascchCWMoMmN5KvUKyUrEsmRAyLWhag-ITcHHp3vvsYMPR664KNN5kWuyFoxkAUSlCQEb07oNZ3IXis9c67rfFfmoLeC9Jr_UeQ3gvSwHQUFNPT46JhtcXqN_tjJALzA4Dx3U-HXgfrsLWx0aPtddW5fy36BiGne6Q</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>Hirtz, Deborah</creator><creator>Kirkham, Fenella J.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2443-7958</orcidid></search><sort><creationdate>201906</creationdate><title>Sickle Cell Disease and Stroke</title><author>Hirtz, Deborah ; Kirkham, Fenella J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-d2c7c3681335c02829103a877263d50504c12aea5a83be4b98f7244c434f86093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Anemia, Sickle Cell - complications</topic><topic>Anemia, Sickle Cell - diagnostic imaging</topic><topic>Anemia, Sickle Cell - therapy</topic><topic>Blood Transfusion - trends</topic><topic>Cerebral blood flow</topic><topic>Cerebrovascular Circulation - physiology</topic><topic>Hemorrhage</topic><topic>Humans</topic><topic>Hydroxyurea</topic><topic>Hydroxyurea - therapeutic use</topic><topic>Silent infarction</topic><topic>Stroke - diagnostic imaging</topic><topic>Stroke - etiology</topic><topic>Stroke - therapy</topic><topic>Transcranial Doppler</topic><topic>Transfusion therapy</topic><topic>Ultrasonography, Doppler, Transcranial - trends</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hirtz, Deborah</creatorcontrib><creatorcontrib>Kirkham, Fenella J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hirtz, Deborah</au><au>Kirkham, Fenella J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sickle Cell Disease and Stroke</atitle><jtitle>Pediatric neurology</jtitle><addtitle>Pediatr Neurol</addtitle><date>2019-06</date><risdate>2019</risdate><volume>95</volume><spage>34</spage><epage>41</epage><pages>34-41</pages><issn>0887-8994</issn><eissn>1873-5150</eissn><abstract>Cerebral infarction is a common complication of sickle cell disease and may manifest as overt stroke or cognitive impairment associated with “silent” cerebral infarction on magnetic resonance imaging. Vasculopathy may be diagnosed on transcranial Doppler or magnetic resonance angiography. The risk factors in sickle cell disease for cognitive impairment, overt ischemic stroke, silent cerebral infarction, overt hemorrhagic stroke, and vasculopathy defined by transcranial Doppler or magnetic resonance angiography overlap, with severe acute and chronic anemia, acute chest crisis, reticulocytosis, and low oxygen saturation reported with the majority. However, there are differences reported in different cohorts, which may reflect age, geographic location, or neuroimaging techniques, for example, magnetic resonance imaging field strength. Regular blood transfusion reduces, but does not abolish, the risk of neurological complications in children with sickle cell disease and either previous overt stroke or silent cerebral infarction or abnormal transcranial Doppler. There are relatively few data on the use of hydroxyurea or other management strategies. Early assessment of the risk of neurocognitive complications is likely to become increasingly important in the management of sickle cell disease.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30948147</pmid><doi>10.1016/j.pediatrneurol.2019.02.018</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-2443-7958</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0887-8994
ispartof Pediatric neurology, 2019-06, Vol.95, p.34-41
issn 0887-8994
1873-5150
language eng
recordid cdi_proquest_miscellaneous_2204694108
source MEDLINE; Elsevier ScienceDirect Journals
subjects Anemia, Sickle Cell - complications
Anemia, Sickle Cell - diagnostic imaging
Anemia, Sickle Cell - therapy
Blood Transfusion - trends
Cerebral blood flow
Cerebrovascular Circulation - physiology
Hemorrhage
Humans
Hydroxyurea
Hydroxyurea - therapeutic use
Silent infarction
Stroke - diagnostic imaging
Stroke - etiology
Stroke - therapy
Transcranial Doppler
Transfusion therapy
Ultrasonography, Doppler, Transcranial - trends
title Sickle Cell Disease and Stroke
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T20%3A43%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sickle%20Cell%20Disease%20and%20Stroke&rft.jtitle=Pediatric%20neurology&rft.au=Hirtz,%20Deborah&rft.date=2019-06&rft.volume=95&rft.spage=34&rft.epage=41&rft.pages=34-41&rft.issn=0887-8994&rft.eissn=1873-5150&rft_id=info:doi/10.1016/j.pediatrneurol.2019.02.018&rft_dat=%3Cproquest_cross%3E2204694108%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2204694108&rft_id=info:pmid/30948147&rft_els_id=S0887899418313055&rfr_iscdi=true